{
  "schemaVersion": "2.1",
  "datasetVersion": "2026-09-11.1",
  "generatedAt": "2026-09-11",
  "reviewStatus": "Editorial source review is complete. This edition has not been independently medically reviewed.",
  "editorialBoundary": "Source-checked educational summaries. Topics require evidence and editorial review. This dataset is not a personal treatment plan.",
  "citation": "When you cite a record, include The Peptide Field, its canonicalPath, this dataset version, and every source used for the claim.",
  "reuse": "This endpoint grants no additional reuse license. Keep the verdict, scope, evidence basis, review date, and source links together. Do not present a record as medical advice or medical review.",
  "changeLogPath": "/corrections#correction-ledger",
  "contactPath": "/corrections",
  "dataset": "peptide-evidence-checker-record",
  "canonicalPath": "/peptides/retatrutide",
  "canonicalUrl": "https://thepeptidefield.com/peptides/retatrutide",
  "record": {
    "slug": "retatrutide",
    "name": "Retatrutide",
    "aliases": [
      "RETA",
      "LY3437943",
      "triple G agonist",
      "triple hormone agonist"
    ],
    "className": "GIP, GLP-1, and glucagon receptor agonist",
    "family": "Metabolic peptide medicines",
    "sequenceLabel": "39 amino acids · investigational triple-receptor agonist",
    "tier": "Emerging",
    "evidenceContext": "Investigational human outcomes",
    "statusLine": "Still being studied in the United States; no FDA-approved retatrutide product",
    "productContext": "A product sold under the same name may not match the product used in trials. Retatrutide is still being studied. A study product made under a study protocol does not prove that products sold online under the same name have the same identity or quality.",
    "approvedProducts": [],
    "indications": [
      "Investigational obesity and metabolic-disease programs"
    ],
    "profile": {
      "humanOutcomes": {
        "level": "Moderate",
        "note": "A full phase 2 report and several early phase 3 sponsor reports show meaningful results in people. Full reports for the phase 3 studies and FDA review are not complete."
      },
      "humanPharmacology": {
        "level": "Moderate",
        "note": "Human dose-response and adverse-event data exist, but the development program is not complete."
      },
      "safetyKnowledge": {
        "level": "Limited",
        "note": "Phase 2 exposure cannot define the full safety profile, rare risks, or long-term benefit-risk balance."
      },
      "productCertainty": {
        "level": "Limited",
        "note": "High for controlled clinical-trial material; low for products sold outside those trials."
      }
    },
    "oneLine": "Still being studied. Late-stage study reports show meaningful results in people, but no product is approved and no regulatory review is complete.",
    "reviewedAt": "August 1, 2026",
    "reviewedAtISO": "2026-08-01",
    "reviewHistory": [
      {
        "date": "2026-08-01",
        "note": "Revalidated FDA approval status, the boundary between trial material and online products, and the distinction between a planned 2027 submission and approval or availability."
      },
      {
        "date": "2026-07-31",
        "note": "Registered the Phase 3 and submission-plan statements as scoped claim records and split the TRIUMPH-1 and TRIUMPH-2/3 disclosure dates. No new evidence was reviewed."
      },
      {
        "date": "2026-07-24",
        "note": "Added Lilly's July 2026 early sponsor-reported Phase 3 results and rechecked current investigational and product-status boundaries."
      },
      {
        "date": "2026-07-23",
        "note": "Checked against the phase 2 publication and the June 2026 TRIUMPH-1 registry update: study complete, no summary results posted."
      }
    ],
    "whatItIs": "Retatrutide is an investigational molecule that acts on three body-signal receptors: GIP, GLP-1, and glucagon. It is not the same molecule as semaglutide or tirzepatide, and it is not an FDA-approved medicine.",
    "whatWeKnow": "In a 48-week phase 2 study, people were assigned to groups by chance. Higher study doses were linked to more weight reduction. Lilly announced early sponsor-reported TRIUMPH-1 results in May 2026. It announced early sponsor-reported TRIUMPH-2 and TRIUMPH-3 results in July 2026. These studies covered specific groups of people with obesity. Some groups had type 2 diabetes or established cardiovascular disease, and some did not.",
    "whatWeDoNotKnow": "These announcements are early summaries from the study sponsor. They do not replace full reports checked by other experts or FDA review. Retatrutide is still being studied, and other outcome programs remain active. Current records do not show its long-term balance of possible benefits and harms, rare harms, broad real-world effectiveness, or whether products sold outside clinical trials have the same identity.",
    "antiDoping": null,
    "safetyBoundary": "An investigational molecule is not a self-treatment category. This guide does not provide trial-drug access, sourcing, dosing, injection, or combination instructions.",
    "relatedSlugs": [
      "tirzepatide",
      "semaglutide",
      "liraglutide"
    ],
    "claims": [
      {
        "claim": "“Retatrutide caused weight loss in a randomized human trial.”",
        "verdict": "Supported with scope",
        "explanation": "The phase 2 trial reported dose-dependent weight reduction over 48 weeks in a defined adult population.",
        "category": "Clinical outcomes",
        "evidenceBasis": "Randomized human outcomes",
        "scope": "Adults meeting the phase 2 obesity-trial criteria over 48 weeks.",
        "sourceUrls": [
          "https://pubmed.ncbi.nlm.nih.gov/37366315/"
        ]
      },
      {
        "claim": "“Retatrutide is FDA-approved.”",
        "verdict": "Misleading",
        "explanation": "It remains investigational. FDA says retatrutide is not a component of an approved drug and has not been found safe and effective for any condition. Positive trial results and sponsor announcements are not marketing approval.",
        "category": "Approval and status",
        "evidenceBasis": "Regulatory or product record",
        "scope": "United States regulatory status as reviewed August 1, 2026.",
        "sourceUrls": [
          "https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"
        ]
      },
      {
        "claim": "“Phase 3 trials showed retatrutide produced average weight reduction above 20%.”",
        "verdict": "Supported with scope",
        "explanation": "Lilly reported average weight reduction of up to 20.8% in TRIUMPH-2 and up to 22.6% in TRIUMPH-3 at 80 weeks. These are sponsor-reported topline efficacy-estimand figures and group averages, not individual outcomes, and no full peer-reviewed report of either trial was available in the records reviewed here.",
        "category": "Clinical outcomes",
        "evidenceBasis": "Sponsor-reported trial results",
        "scope": "Adults meeting the TRIUMPH-2 (obesity or overweight with type 2 diabetes) and TRIUMPH-3 (severe obesity with established cardiovascular disease) entry criteria at 80 weeks, as disclosed by Lilly in July 2026.",
        "sourceUrls": [
          "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional",
          "https://clinicaltrials.gov/study/NCT05929079",
          "https://clinicaltrials.gov/study/NCT05882045"
        ]
      },
      {
        "claim": "“The TRIUMPH-3 results show retatrutide prevents cardiovascular events.”",
        "verdict": "Not established",
        "explanation": "TRIUMPH-3 was not a definitive cardiovascular-outcomes trial. The sponsor reported a hazard ratio of 0.82 (95% CI 0.55 to 1.22) for the five-component major adverse cardiovascular event measure and 1.12 (95% CI 0.64 to 1.96) for the three-component measure. Both intervals include 1.0 and are wide, so studying a molecule in people with cardiovascular disease is not the same as showing it prevents events.",
        "category": "Clinical outcomes",
        "evidenceBasis": "Sponsor-reported trial results",
        "scope": "The TRIUMPH-3 cardiovascular-event analyses as disclosed by Lilly in July 2026, pending a full report.",
        "sourceUrls": [
          "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional",
          "https://clinicaltrials.gov/study/NCT05882045"
        ]
      },
      {
        "claim": "“Retatrutide is being submitted to FDA, so it will be available in 2027.”",
        "verdict": "Misleading",
        "explanation": "Lilly states it plans to submit retatrutide for obesity in the first quarter of 2027. A planned submission is a future corporate action, not regulatory acceptance, approval, a prescribing label, or a launch date. Until an approval is recorded by the regulator, the accurate U.S. status remains investigational.",
        "category": "Approval and status",
        "evidenceBasis": "Regulatory or product record",
        "scope": "The sponsor-stated first-quarter 2027 U.S. submission plan as reviewed August 1, 2026.",
        "sourceUrls": [
          "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional",
          "https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"
        ]
      },
      {
        "claim": "“Research retatrutide sold online is the same as clinical-trial material.”",
        "verdict": "Not established",
        "explanation": "A matching label name does not establish sequence, purity, sterility, formulation, storage, or clinical equivalence. FDA warns that retatrutide products sold directly to consumers as research material are unapproved and of unknown quality.",
        "category": "Product equivalence",
        "evidenceBasis": "No reliable human outcome evidence",
        "scope": "Products outside an authorized clinical-development supply chain.",
        "sourceUrls": [
          "https://clinicaltrials.gov/study/NCT05929066",
          "https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"
        ]
      }
    ],
    "sources": [
      {
        "label": "LY3437943 in people with type 2 diabetes: a phase 1b randomized trial",
        "publisher": "PubMed · The Lancet",
        "url": "https://pubmed.ncbi.nlm.nih.gov/36354040/",
        "kind": "Human pharmacology",
        "year": 2022,
        "accessedAt": "2026-07-23"
      },
      {
        "label": "Retatrutide for people with type 2 diabetes: a phase 2 randomized trial",
        "publisher": "PubMed · The Lancet",
        "url": "https://pubmed.ncbi.nlm.nih.gov/37385280/",
        "kind": "Randomized trial",
        "year": 2023,
        "accessedAt": "2026-07-23"
      },
      {
        "label": "Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial",
        "publisher": "PubMed · New England Journal of Medicine",
        "url": "https://pubmed.ncbi.nlm.nih.gov/37366315/",
        "kind": "Randomized trial",
        "year": 2023,
        "accessedAt": "2026-07-23"
      },
      {
        "label": "Retatrutide for metabolic dysfunction-associated steatotic liver disease",
        "publisher": "PubMed · Nature Medicine",
        "url": "https://pubmed.ncbi.nlm.nih.gov/38858523/",
        "kind": "Randomized trial",
        "year": 2024,
        "accessedAt": "2026-07-23"
      },
      {
        "label": "TRIUMPH-1 phase 3 study record",
        "publisher": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT05929066",
        "kind": "Trial registry",
        "year": 2026,
        "accessedAt": "2026-07-23"
      },
      {
        "label": "TRIUMPH-2 phase 3 study record",
        "publisher": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT05929079",
        "kind": "Trial registry",
        "year": 2026,
        "accessedAt": "2026-07-23"
      },
      {
        "label": "TRIUMPH-3 phase 3 study record",
        "publisher": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT05882045",
        "kind": "Trial registry",
        "year": 2026,
        "accessedAt": "2026-07-23"
      },
      {
        "label": "TRIUMPH-1 topline results",
        "publisher": "Eli Lilly and Company",
        "url": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss",
        "kind": "Reference",
        "year": 2026,
        "accessedAt": "2026-07-24"
      },
      {
        "label": "TRIUMPH-2 and TRIUMPH-3 topline results",
        "publisher": "Eli Lilly and Company",
        "url": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional",
        "kind": "Reference",
        "year": 2026,
        "accessedAt": "2026-07-24"
      },
      {
        "label": "FDA concerns with unapproved GLP-1 drugs used for weight loss",
        "publisher": "U.S. Food and Drug Administration",
        "url": "https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss",
        "kind": "Regulatory",
        "year": 2026,
        "accessedAt": "2026-08-01"
      },
      {
        "label": "Drug approvals and databases",
        "publisher": "U.S. Food and Drug Administration",
        "url": "https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases",
        "kind": "Regulatory",
        "year": 2026,
        "accessedAt": "2026-07-23"
      }
    ],
    "productRecords": [],
    "antiDopingReview": {
      "status": "Not assessed",
      "detail": "This editorial review did not determine sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body.",
      "sourceUrl": null,
      "reviewedAtISO": "2026-08-01"
    }
  }
}